Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2011-08-23
2011-08-23
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S234100, C424S203100, C424S184100, C424S244100, C424S250100, C424S242100, C424S831000, C536S123100
Reexamination Certificate
active
08003112
ABSTRACT:
This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to bothS. pneumoniaeandN. meningitidesin a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) fromS. pneumoniaeand capsular polysaccharide fromN. meningitidisserogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 5773007 (1998-06-01), Penney et al.
patent: 5849301 (1998-12-01), Lees
patent: 6756040 (2004-06-01), Peetermans et al.
patent: 2003/0035806 (2003-02-01), D'Ambra et al.
patent: 2003/0068336 (2003-04-01), Ryall
patent: 2005/0002948 (2005-01-01), Ryall
patent: 2007/0065462 (2007-03-01), Ryall
patent: 2007/0141084 (2007-06-01), Lee et al.
patent: 2005/037320 (2005-04-01), None
A.E. Tutton. “The Isolation of Hydrazine.” Nature, 1891, 1105, pp. 205-206.
A. Bartoloni et al., “Immunogenicity of Meningococcal B Polysaccharide Conjugated to Tetanus Toxoid or CRM197 Via Adipic Acid Dihydrazide.” Vaccine, 1995, vol. 13, No. 5, pp. 463-470.
Z. Guo et al., “Protein-Polysaccharide Conjugation.” Methods in Molecular Medicine, Meningococcal Vaccines: Methods and Protocols, 2001, Humana Press Inc., Totowa N.J., vol. 66, pp. 49-54.
H. Jennings et al., “Immunochemistry of Groups A, B, and C Meningococcal Polysaccharide-Tetanus Toxoid Conjugates.” Journal of Immunology, 1981, vol. 127, No. 3, pp. 1011-1018.
E. Konadu et al., “Phase 1 and 2 Studies ofSalmonella entericaSerovar Paratyphi A O-Specific Polysaccharide-Tetanus Toxoid Conjugates in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam.” Infection and Immunity, Mar. 2000, vol. 68, No. 3, pp. 1529-1534.
C.-J Lee et al., “Quality Control of Polyvalent Pneumococcal Polysaccaride-Protein Conjugate Vaccine by Nephelometry.” Biologicals, 2002, vol. 30, pp. 97-103.
A. Lees et al., “Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridinium Tetrafluoroborate for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents.” Vaccine, 1996, vol. 14, No. 3, pp. 190-198.
D. Shafer et al., “Activation of Soluble Polysaccharides with 1-Cyano 4-Dimethylaminopyridinium Tetrafluoroborate (CDAP) For Use in Protein-Polysacharides Conjugate Vaccines and Immunological Reagents. II. Selective Crosslinking of Proteins to CDAP-Activated Polysaccharides.” Vaccine, 2000, vol. 18, pp. 1273-1281.
International Application No. PCT/US2010/031083, Notification of Transmittal of the International Search Report and the Written opinion of the International Searching Authority, or the Declaration, date of mailing Aug. 6, 2010, 7 pages.
Lee Che-Hung Robert
Tai Stanley Shih-Peng
Devi S.
Fitch Even Tabin & Flannery
Howard University
The United States of America as represented by the Secretary, De
LandOfFree
Meningococcal and pneumococcal conjugate vaccine and method... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Meningococcal and pneumococcal conjugate vaccine and method..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meningococcal and pneumococcal conjugate vaccine and method... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712405